Industrifonden strengthens its Life Science team
Industrifonden strengthens its Life Science investment team by recruiting Patrik Sobocki as Investment Manager. Patrik has extensive experience from the pharmaceutical industry, academic research and developing startup companies.
Before joining Industrifonden, Patrik Sobocki held the position of European Chief Operating Officer for the business area Real World Evidence at IMS Health, the world’s leading provider of information and technology services to the healthcare industry. The role included responsibility for IMS Health’s M&A strategy within Real World Evidence. At Industrifonden, Patrik will focus on developing the current investment portfolio, as well as on new investments, primarily within digital health.
– Industrifonden continuously strives to secure high-quality and up-to-date understanding of our core investment areas. Patrik’s thorough knowledge of health economics and its impact on the health care sector’s willingness to pay, combined with his experience in digital health, will be a significant contribution to our team, says Nina Rawal, Head of Life Science at Industrifonden.
Prior to his employment at IMS Health, Patrik has led two startup companies, most recently in a role as CEO at Pygargus, which was acquired by IMS Health in 2013. Patrik holds a M.Sc. in Economics and Finance from Stockholm School of Economics, as well as a Ph.D. in health economics from Karolinska Institutet. He is currently an Associate Professor at Karolinska Institutet, where he supervises both undergraduate and graduate students in health economics.
– Based on my experience as an entrepreneur, as well as from acquiring startup companies, I look forward to contributing to strengthen Industrifonden’s position within the area of life science in general and digital health in particular. I am proud to become a part of a professional and tight team with a sharp eye for identifying and developing the successful companies of tomorrow, says Patrik Sobocki.
Industrifonden is one of the Nordic region’s most active investors in the Life Science area, with a focus on pharmaceuticals, medtech and digital health. Industrifonden's current holdings include Pharmalink, BONESUPPORT and AMRA.
For more information, please contact
Nina Rawal, Head of Life Science, Industrifonden
Phone: +46 70-515 01 89, nina.rawal@industrifonden.com
Sara Mattsson, Communication, Industrifonden
Phone: +46 70-878 77 58, sara.mattsson@industrifonden.com
About Industrifonden
Industrifonden is a Nordic venture capital investor focusing on early stage life science and technology companies with global potential. Industrifonden is an active partner to companies with ground-breaking ideas and capacity to grow. Industrifonden is an evergreen fund with SEK 4 billion ($500 million) in assets. More info: Web, Twitter, LinkedIn.
Tags:
